Previous article Next article

Mergers in the pharmaceutical sector: An overview of EU and national case law

In the past ten years or so, e-Competitions' Bulletin has regularly reported about pharmaceutical merger control decisions or judgments from various jurisdictions in the world. Many of these cases involved remedies that were meant to address the antitrust concerns that the competent competition authority had identified. The list of reported cases is impressive but not exhaustive. Although merger cases are, by their very nature, facts specific, the present foreword attempts to capture some themes of more general interest. We will refer to a few recent EU cases not covered by the national reports but with these additional references, we do not claim to achieve completeness. Our sole ambition is to flag a couple of themes that the reader might find helpful when reading “the next case”

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Arnold & Porter Kaye Scholer (Brussels)

Quotation

Luc Gyselen, Mergers in the pharmaceutical sector: An overview of EU and national case law, 5 March 2015, e-Competitions Pharma & Mergers, Art. N° 44608

Visites 568

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues